I agree that on a straight our sale of Race the company, it is unlikely investors will have no choice. In these scenarios, the only possible options is to take cash, and if offered, take shares in the acquiring company or a combination.
I am simply sharing there are many other possibilities than a straight out sale of Race the company.
IMO the mood for commercialization has shifted from a straight out sale circa 2020 to a licensing the solution owing to all the new research such as FTO, CPACS, MOPACS and synergy chemo drugs and potentially assist 29 known cancers.
Further is Race want to progress the other 29 molecules, then they may only sell BIS and not the company at all.
You can ignore the licensing scenarios if you like, but they remain very real options in the shorter term. I speculate the reason for the blackout since June last year is possible licensing discussions that PS has been working on. (It was mentioned PS was working on something to end the blackout in some interview/preso).
Good luck to you.
RAC Price at posting:
$1.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)